CEP55 and prostate adenocarcinoma: Moreover, patients with recurrences during follow-up showed increased expression of CEP55 in ACC, KIRP, KICH, LIHC, LGG, PRAD, pheochromocytoma and paraganglioma (PCPG), UCEC, SARC, and uveal melanoma (UVM), and reduced expression in STAD (Figure 2F).